analyzeportfolio
NYSE · Healthcare

Glass House Brands Inc. (GLAS)

As-reported financials and SEC filings for Glass House Brands Inc. The latest annual period is FY2025. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

About Glass House Brands Inc.

Glass House Brands Inc. is a vertically integrated cannabis company based in California. It operates through its subsidiary GH Group, which it acquired in a business combination. The company produces and sells cannabis products and serves customers in the cannabis market.

Snapshot

Revenue
$182.0M
Revenue growth (YoY)
-9.4%
Net income
$-29.7M
Diluted EPS
$-0.55
Gross margin
42.3%
Operating margin
-9.1%
Net margin
-16.3%
FCF margin
-8.6%
ROE
—
net income / fiscal-year-end equity
P/E
n/m
not meaningful: a reported loss in the fiscal year or the trailing twelve months
Market cap
$349.6M
Long-term debt / equity
—
non-current term debt only

Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at Glass House Brands

  • Revenue fell 9.4% to $182M in FY2025, slower than the 24.9% the year before.
  • Operating margin is -9.1% in FY2025, +48.2 pp against -57.2% in FY2021.
  • Free cash flow was negative $16M in FY2025.
  • Net income turned to a $30M loss in FY2025, from a $519000 profit in FY2024.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where Glass House Brands’s fundamentals sit among the 570 Healthcare companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Gross margin42.3%
27th percentile of 290
Operating margin-9.1%
36th percentile of 410
Net margin-16.3%
30th percentile of 429
FCF margin-8.6%
27th percentile of 385
Revenue growth (YoY)-9.4%
17th percentile of 552
Short interest1.00d
1st percentile of 568

No reported insider purchases (code P) in the last 90 days; 1 insider sale totaling $30,659. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 1 quant / multi-strat book among the superinvestors we track; no conviction manager currently reports a position.

Conviction investors
0
+1 quant / multi-strat
Initiated / added
1
1 new, 0 added
Reduced / exited
0
0 trimmed, 0 exited
Combined position
$4.5M
reported long value
InvestorAs ofPosition valueSharesChange
Millennium ManagementquantQ2 2026$4.5M362.9KNew

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
0
code P
Bought (90d)
—
code P value
Sells (90d)
1
$31K
Reported activity
Net selling
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-09-11
William TuSVP, Corporate ControllerSell3.8K$8.03$31K

Reported non-derivative purchases and sales (codes P/S), which may be open-market or private. Excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
378.7K
settled 2026-09-30
Change vs prior
+89.6%
vs previous settlement
Days to cover
1.00
at avg daily volume
Avg daily volume
1.5M
FINRA reported
SettlementShares shortChangeDays to cover
2026-09-30378.7K+89.6%1.00
2026-09-15199.8K+8.6%1.00
2026-08-31183.9K-47.8%1.00
2026-08-14352.3K+17.2%1.00
2026-07-31300.5K+108.4%1.00
2026-07-15144.2K+83.5%1.00
2026-06-3078.6K-0.6%1.00

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2025FY2024FY2023FY2022FY2021
Revenue$182.0M$200.9M$160.8M$84.9M$63.2M
Gross profit
Operating income$-16.5M$5.7M$-49.5M$-56.4M$-36.2M
Net income$-29.7M$519,000$-98.3M$-32.9M$-43.1M
Diluted EPS$-0.55$-0.21$-1.62$-0.83$-1.11

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.

Balance sheet (as reported)

 FY2025FY2024FY2023FY2022FY2021
Cash and equivalents$23.4M$36.9M$32.5M$14.1M$54.1M
Current assets$67.7M$66.1M$49.2M$38.9M$68.6M
Total assets$318.6M$310.5M$303.8M$350.6M$287.6M
Current liabilities$38.0M$66.5M$87.4M$54.0M$55.2M
Long-term debt$68.6M$50.6M$56.5M$62.6M$44.8M
Total liabilities$144.0M$146.4M$158.5M$129.5M$105.6M
Total equity$116.2M$89.8M$168.9M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2025FY2024FY2023FY2022FY2021
Operating cash flow$11.4M$28.4M$23.2M$-40.8M$-20.3M
Capital expenditure$27.2M$10.3M$12.3M$27.8M$108.5M
Free cash flow

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.

Company facts

ExchangeNYSE
SectorHealthcare
SIC industryMedicinal Chemicals & Botanical Products
Latest annual periodFY2025 (ended December 31, 2025)
Oldest indexed filing2021
SEC CIK1848731

Selected SEC filings

40-F2026-03-24
View on EDGAR →
40-F2025-03-25
View on EDGAR →
6-K2026-10-09
View on EDGAR →
6-K2026-09-29
View on EDGAR →
6-K2026-09-11
View on EDGAR →
6-K2026-08-14
View on EDGAR →

Largest Healthcare peers

All Healthcare companies →

Monitor GLAS

Get an alert when Glass House Brands files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor GLAS free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.